A detailed history of Charles Schwab Investment Management Inc transactions in Ocugen, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 170,254 shares of OCGN stock, worth $274,108. This represents 0.0% of its overall portfolio holdings.

Number of Shares
170,254
Previous 170,254 -0.0%
Holding current value
$274,108
Previous $97,000 187.63%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 08, 2023

SELL
$0.4 - $0.62 $385,506 - $597,534
-963,766 Reduced 84.99%
170,254 $68,000
Q2 2023

Aug 09, 2023

SELL
$0.45 - $0.88 $173,163 - $338,631
-384,808 Reduced 25.34%
1,134,020 $612,000
Q1 2023

May 11, 2023

SELL
$0.82 - $1.33 $83,211 - $134,965
-101,478 Reduced 6.26%
1,518,828 $1.29 Million
Q4 2022

Feb 13, 2023

BUY
$1.11 - $1.87 $68,626 - $115,614
61,826 Added 3.97%
1,620,306 $2.11 Million
Q3 2022

Nov 14, 2022

BUY
$1.75 - $3.1 $62,728 - $111,119
35,845 Added 2.35%
1,558,480 $2.78 Million
Q2 2022

Aug 15, 2022

BUY
$1.83 - $3.45 $204,473 - $385,482
111,734 Added 7.92%
1,522,635 $3.46 Million
Q1 2022

May 13, 2022

BUY
$2.34 - $4.72 $92,837 - $187,261
39,674 Added 2.89%
1,410,901 $4.66 Million
Q4 2021

Feb 11, 2022

BUY
$4.38 - $15.67 $88,068 - $315,076
20,107 Added 1.49%
1,371,227 $6.24 Million
Q3 2021

Nov 16, 2021

BUY
$6.36 - $8.51 $5.62 Million - $7.52 Million
883,662 Added 189.04%
1,351,120 $9.7 Million
Q2 2021

Aug 16, 2021

BUY
$5.52 - $15.68 $2.2 Million - $6.26 Million
399,181 Added 584.65%
467,458 $3.75 Million
Q1 2021

May 17, 2021

BUY
$1.66 - $15.81 $113,339 - $1.08 Million
68,277 New
68,277 $464,000

Others Institutions Holding OCGN

About Ocugen, Inc.


  • Ticker OCGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 216,566,000
  • Market Cap $349M
  • Description
  • Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...
More about OCGN
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.